ArticleAesthetic plastic surgery2026
Clinical Characteristics and Use of Poly-4-Hydroxybutyrate Scaffold (GalaFLEX™) in Primary and Secondary Implant-Based Breast Reconstruction: A Structured Review of the Literature and Preliminary Single-Center Experience.
Article in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoly-4-hydroxybutyrate (P4HB, e.g., GalaFLEX™) is a bioabsorbable matrix with a broad spectrum of indications in surgery. However, there is a lack of evidence and data on its utilization in Europe in the breast reconstruction setting.
objectiveTo report preliminary clinical experience with P4HB scaffolds in implant-based breast reconstruction, with a focus on operative technique and complication predictors, complemented by a structured literature review.
methodsThis single-center retrospective study included 20 patients with 31 operated breasts, who underwent mastectomy with implant-based reconstruction in combination with P4HB scaffold. Patient-specific and mastectomy-specific factors were evaluated in the timeframe from January 2024 to January 2025. Statistical analyses were performed using nonparametric and regression-based methods.
resultsMajor complications were recorded for 25.8% of breasts. Higher BMI was associated with increased risk of seroma formation (p = 0.044). Lower resection weight was associated with more frequent rippling/asymmetry (p = 0.011) and showed a trend toward skin and/or NAC necrosis (p = 0.057), whereas smaller implants were linked to necrosis of the skin envelope (p = 0.027), and larger implants to seroma formation (p = 0.031). The Stewart approach mastectomy had lowest rates of seromas (p = 0.022). The specific P4HB utilization technique did not show significant associations with reported outcomes. More rippling/asymmetry were observed when P4HB was used without additional dermal or muscle flaps (28% vs. 0%). Our structured review identified 4 studies with 418 operated breasts where P4HB was utilized. Overall complication rate reached up to 43%, and two authors have reported about an increased risk of capsular contracture in P4HB-patients.
conclusionP4HB scaffolds did not show an increased complication signal in this exploratory cohort. Mastectomy-specific and anatomical factors seem to be the most consistent predictors of early complications. Our data suggest that a conservative implant sizing strategy may be beneficial in selected patients. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42716980What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.